Literature DB >> 32206693

Brief outcome of five decades of battle with infectious diseases in Iran.

Vahid Lohrasbi1,2, Nima Mohammadzadeh3, Neda Shirmohammadlou4.   

Abstract

According to WHO health profile, Iran has better situation in controlling some infection disease like leprosy, dengue fever, tularemia and hepatitis B than United States, even though Iran is in a more dangerous area than the USA. Achieving optimum control for infectious disease in the Middle East requires huge financial costs, equipment and a great time. Some of Iran's actions to control infectious diseases include: special attention of the Iran government to the health issue, training and developing human resources, membership and close cooperation with international organizations like WHO, detecting and monitoring emerging diseases before their arrival and distribution in Iran, expanding and updating national immunization and vaccination program since 1992, national project implementation titled "Health system development plan", supplying and manufacturing most of drugs required in Iran by the Iranian companies as a strategic planning, great coordination between different departments of the MOHME and other relevant institutions to Iran Army and Ministry of Intelligence to prevent the emergence of bioterrorism, and etc. We believe that Iran has obtained an acceptable score in the control of infectious diseases; but it still has very big challenges to reach the ideal level. © Indian Virological Society 2020.

Entities:  

Year:  2020        PMID: 32206693      PMCID: PMC7085491          DOI: 10.1007/s13337-019-00565-y

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  2 in total

Review 1.  Overview of Zoonotic Diseases in Turkey: The One Health Concept and Future Threats.

Authors:  Abdullah İnci; Mehmet Doğanay; Aykut Özdarendeli; Önder Düzlü; Alparslan Yıldırım
Journal:  Turkiye Parazitol Derg       Date:  2018-03

Review 2.  Infection control as a major World Health Organization priority for developing countries.

Authors:  D Pittet; B Allegranzi; J Storr; S Bagheri Nejad; G Dziekan; A Leotsakos; L Donaldson
Journal:  J Hosp Infect       Date:  2008-03-10       Impact factor: 3.926

  2 in total
  1 in total

1.  A glance at the prevalence of coronavirus disease 19 (COVID-19) in Iran: Strengths and weaknesses.

Authors:  Nima Mohammadzadeh; Mahla Shahriary; Neda Shirmohammadlou; Vahid Lohrasbi
Journal:  Infect Control Hosp Epidemiol       Date:  2020-05-04       Impact factor: 3.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.